Equity Overview
Price & Market Data
Price: $9.05
Daily Change: $0.00 / 0.00%
Range: $8.50 - $9.40
Market Cap: $700,838,144
Volume: 201,134
Performance Metrics
1 Week: 3.59%
1 Month: -13.11%
3 Months: -33.67%
6 Months: -24.40%
1 Year: 43.44%
YTD: -25.02%
Company Details
Employees: 331
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.